<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05081154</url>
  </required_header>
  <id_info>
    <org_study_id>CSD201002</org_study_id>
    <nct_id>NCT05081154</nct_id>
  </id_info>
  <brief_title>CSD201002: Study to Assess Nicotine Uptake From P10 Nicotine Pouches</brief_title>
  <official_title>An In-Clinic Confinement Study to Assess Nicotine Uptake From P10 Nicotine Pouches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RAI Services Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RAI Services Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, open-label, randomized, 7-way crossover study designed to&#xD;
      evaluate plasma nicotine pharmacokinetics (PK) parameters following use of the study&#xD;
      investigational products (IPs) in a confinement setting by generally healthy combustible&#xD;
      cigarette (CC) smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate plasma nicotine PK parameters following the use of&#xD;
      nicotine pouches (hereinafter referred to as Velo Pouch IPs) in cigarette smokers and smokers&#xD;
      who also use smokeless tobacco (SST) [e.g., snus, moist snuff]. At least one-third of the&#xD;
      study population will include smokers who also use ST.&#xD;
&#xD;
      Potential subjects may complete a pre-screening telephone interview. They will complete a&#xD;
      Screening Visit to assess their eligibility within 45 days prior to enrollment, randomization&#xD;
      and confinement.&#xD;
&#xD;
      Following the Screening Visit, eligible subjects will be scheduled for a Day 1 check-in visit&#xD;
      to complete procedures to confirm eligibility. Eligible subjects will be enrolled and begin&#xD;
      confinement at the clinical site for 8 days and 7 nights. Subjects will participate in&#xD;
      separate Test Sessions for plasma nicotine PK assessment, one for each IP. The IP for each&#xD;
      Test Session will be determined based on a randomly assigned IP presentation schedule (14&#xD;
      product sequence) generated using a Williams Design. Each Test Session will last for&#xD;
      approximately 4 hours following the start of the IP use, and will include collection of&#xD;
      plasma samples for PK assessments prior to, during and following IP use and completion of the&#xD;
      Overall Product Liking questionnaire. Subjects will use their randomized study IP one day&#xD;
      before the respective test session to familiarize themselves with the IP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">January 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC nic 0-240</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Baseline-adjusted area under the plasma nicotine concentration-versus-time curve from time zero to 240 minutes after the start of IP use</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>240 minutes</time_frame>
    <description>Maximum baseline-adjusted plasma concentration of nicotine</description>
  </primary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Smoking</condition>
  <condition>Tobacco Use</condition>
  <arm_group>
    <arm_group_label>Product usage order A B G C F D E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (A B G C F D E) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order B C A D G E F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (B C A D G E F) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order C D B E A F G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (C D B E A F G) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order D E C F B G A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (D E C F B G A) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order E F D G C A B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (E F D G C A B) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order F G E A D B C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (F G E A D B C) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order G A F B E C D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (G A F B E C D) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order E D F C G B A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (E D F C G B A) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order F E G D A C B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (F E G D A C B) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order G F A E B D C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (G F A E B D C) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order A G B F C E D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (A G B F C E D) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order B A C G D F E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (B A C G D F E) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order C B D A E G F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (C B D A E G F) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order D C E B F A G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 7 products (D C E B F A G) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product A</intervention_name>
    <description>P1012915, a nicotine pouch with 8 mg nicotine</description>
    <arm_group_label>Product usage order A B G C F D E</arm_group_label>
    <arm_group_label>Product usage order A G B F C E D</arm_group_label>
    <arm_group_label>Product usage order B A C G D F E</arm_group_label>
    <arm_group_label>Product usage order B C A D G E F</arm_group_label>
    <arm_group_label>Product usage order C B D A E G F</arm_group_label>
    <arm_group_label>Product usage order C D B E A F G</arm_group_label>
    <arm_group_label>Product usage order D C E B F A G</arm_group_label>
    <arm_group_label>Product usage order D E C F B G A</arm_group_label>
    <arm_group_label>Product usage order E D F C G B A</arm_group_label>
    <arm_group_label>Product usage order E F D G C A B</arm_group_label>
    <arm_group_label>Product usage order F E G D A C B</arm_group_label>
    <arm_group_label>Product usage order F G E A D B C</arm_group_label>
    <arm_group_label>Product usage order G A F B E C D</arm_group_label>
    <arm_group_label>Product usage order G F A E B D C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product B</intervention_name>
    <description>P1013018, a nicotine pouch with 10 mg nicotine</description>
    <arm_group_label>Product usage order A B G C F D E</arm_group_label>
    <arm_group_label>Product usage order A G B F C E D</arm_group_label>
    <arm_group_label>Product usage order B A C G D F E</arm_group_label>
    <arm_group_label>Product usage order B C A D G E F</arm_group_label>
    <arm_group_label>Product usage order C B D A E G F</arm_group_label>
    <arm_group_label>Product usage order C D B E A F G</arm_group_label>
    <arm_group_label>Product usage order D C E B F A G</arm_group_label>
    <arm_group_label>Product usage order D E C F B G A</arm_group_label>
    <arm_group_label>Product usage order E D F C G B A</arm_group_label>
    <arm_group_label>Product usage order E F D G C A B</arm_group_label>
    <arm_group_label>Product usage order F E G D A C B</arm_group_label>
    <arm_group_label>Product usage order F G E A D B C</arm_group_label>
    <arm_group_label>Product usage order G A F B E C D</arm_group_label>
    <arm_group_label>Product usage order G F A E B D C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product C</intervention_name>
    <description>P1013015, a nicotine pouch with 8 mg nicotine</description>
    <arm_group_label>Product usage order A B G C F D E</arm_group_label>
    <arm_group_label>Product usage order A G B F C E D</arm_group_label>
    <arm_group_label>Product usage order B A C G D F E</arm_group_label>
    <arm_group_label>Product usage order B C A D G E F</arm_group_label>
    <arm_group_label>Product usage order C B D A E G F</arm_group_label>
    <arm_group_label>Product usage order C D B E A F G</arm_group_label>
    <arm_group_label>Product usage order D C E B F A G</arm_group_label>
    <arm_group_label>Product usage order D E C F B G A</arm_group_label>
    <arm_group_label>Product usage order E D F C G B A</arm_group_label>
    <arm_group_label>Product usage order E F D G C A B</arm_group_label>
    <arm_group_label>Product usage order F E G D A C B</arm_group_label>
    <arm_group_label>Product usage order F G E A D B C</arm_group_label>
    <arm_group_label>Product usage order G A F B E C D</arm_group_label>
    <arm_group_label>Product usage order G F A E B D C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product D</intervention_name>
    <description>P1012815, a nicotine pouch with 8 mg nicotine</description>
    <arm_group_label>Product usage order A B G C F D E</arm_group_label>
    <arm_group_label>Product usage order A G B F C E D</arm_group_label>
    <arm_group_label>Product usage order B A C G D F E</arm_group_label>
    <arm_group_label>Product usage order B C A D G E F</arm_group_label>
    <arm_group_label>Product usage order C B D A E G F</arm_group_label>
    <arm_group_label>Product usage order C D B E A F G</arm_group_label>
    <arm_group_label>Product usage order D C E B F A G</arm_group_label>
    <arm_group_label>Product usage order D E C F B G A</arm_group_label>
    <arm_group_label>Product usage order E D F C G B A</arm_group_label>
    <arm_group_label>Product usage order E F D G C A B</arm_group_label>
    <arm_group_label>Product usage order F E G D A C B</arm_group_label>
    <arm_group_label>Product usage order F G E A D B C</arm_group_label>
    <arm_group_label>Product usage order G A F B E C D</arm_group_label>
    <arm_group_label>Product usage order G F A E B D C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product E</intervention_name>
    <description>P1013315, a nicotine pouch with 8 mg nicotine</description>
    <arm_group_label>Product usage order A B G C F D E</arm_group_label>
    <arm_group_label>Product usage order A G B F C E D</arm_group_label>
    <arm_group_label>Product usage order B A C G D F E</arm_group_label>
    <arm_group_label>Product usage order B C A D G E F</arm_group_label>
    <arm_group_label>Product usage order C B D A E G F</arm_group_label>
    <arm_group_label>Product usage order C D B E A F G</arm_group_label>
    <arm_group_label>Product usage order D C E B F A G</arm_group_label>
    <arm_group_label>Product usage order D E C F B G A</arm_group_label>
    <arm_group_label>Product usage order E D F C G B A</arm_group_label>
    <arm_group_label>Product usage order E F D G C A B</arm_group_label>
    <arm_group_label>Product usage order F E G D A C B</arm_group_label>
    <arm_group_label>Product usage order F G E A D B C</arm_group_label>
    <arm_group_label>Product usage order G A F B E C D</arm_group_label>
    <arm_group_label>Product usage order G F A E B D C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product F</intervention_name>
    <description>P1013115, a nicotine pouch with 8 mg nicotine</description>
    <arm_group_label>Product usage order A B G C F D E</arm_group_label>
    <arm_group_label>Product usage order A G B F C E D</arm_group_label>
    <arm_group_label>Product usage order B A C G D F E</arm_group_label>
    <arm_group_label>Product usage order B C A D G E F</arm_group_label>
    <arm_group_label>Product usage order C B D A E G F</arm_group_label>
    <arm_group_label>Product usage order C D B E A F G</arm_group_label>
    <arm_group_label>Product usage order D C E B F A G</arm_group_label>
    <arm_group_label>Product usage order D E C F B G A</arm_group_label>
    <arm_group_label>Product usage order E D F C G B A</arm_group_label>
    <arm_group_label>Product usage order E F D G C A B</arm_group_label>
    <arm_group_label>Product usage order F E G D A C B</arm_group_label>
    <arm_group_label>Product usage order F G E A D B C</arm_group_label>
    <arm_group_label>Product usage order G A F B E C D</arm_group_label>
    <arm_group_label>Product usage order G F A E B D C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product G</intervention_name>
    <description>P1013215, a nicotine pouch with 8 mg nicotine</description>
    <arm_group_label>Product usage order A B G C F D E</arm_group_label>
    <arm_group_label>Product usage order A G B F C E D</arm_group_label>
    <arm_group_label>Product usage order B A C G D F E</arm_group_label>
    <arm_group_label>Product usage order B C A D G E F</arm_group_label>
    <arm_group_label>Product usage order C B D A E G F</arm_group_label>
    <arm_group_label>Product usage order C D B E A F G</arm_group_label>
    <arm_group_label>Product usage order D C E B F A G</arm_group_label>
    <arm_group_label>Product usage order D E C F B G A</arm_group_label>
    <arm_group_label>Product usage order E D F C G B A</arm_group_label>
    <arm_group_label>Product usage order E F D G C A B</arm_group_label>
    <arm_group_label>Product usage order F E G D A C B</arm_group_label>
    <arm_group_label>Product usage order F G E A D B C</arm_group_label>
    <arm_group_label>Product usage order G A F B E C D</arm_group_label>
    <arm_group_label>Product usage order G F A E B D C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to read, understand, and willing to sign an informed consent form (ICF) and&#xD;
             complete questionnaires written in English.&#xD;
&#xD;
          2. Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of&#xD;
             consent.&#xD;
&#xD;
          3. Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in&#xD;
             length as primary source of tobacco.&#xD;
&#xD;
          4. Smokers who also use ST products (e.g., moist snuff, snus), and have used ST within 30&#xD;
             days prior to screening will be enrolled.&#xD;
&#xD;
          5. Smokes an average of at least 10 cigarettes per day (CPD) and inhale the smoke, for at&#xD;
             least 6 months prior to Screening. Brief periods of abstinence due to illness, quit&#xD;
             attempt (prior to 30 days of Screening), or clinical study participation (prior to 30&#xD;
             days of Screening) will be allowed at the discretion of the PI.&#xD;
&#xD;
          6. Agrees to smoke the same Usual Brand (UB) cigarette throughout the study period. The&#xD;
             UB cigarette is defined as the reported cigarette brand and style currently smoked&#xD;
             most frequently by the subject.&#xD;
&#xD;
          7. Expired breath carbon monoxide (ECO) level is ≥ 10 ppm and ≤ 100 ppm at Screening and&#xD;
             at check-in Day 1.&#xD;
&#xD;
          8. Positive urine cotinine test at Screening.&#xD;
&#xD;
          9. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1&#xD;
             (&quot;How soon after you wake up do you smoke your first cigarette?&quot;) is either &quot;Within 5&#xD;
             minutes&quot; or &quot;6-30 minutes&quot; (Heatherton et al., 1991).&#xD;
&#xD;
         10. Willing to use the UB cigarette and Velo Pouch IPs during the study period.&#xD;
&#xD;
         11. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the&#xD;
             start of each of seven Test Sessions.&#xD;
&#xD;
         12. Females must be willing to use a form of contraception acceptable to the PI from the&#xD;
             time of signing the informed consent until End-of-Study.&#xD;
&#xD;
             Examples of acceptable means of birth control are, but not limited to: a) Surgical&#xD;
             sterilization (hysterectomy, bilateral tubal ligation/occlusion, bilateral&#xD;
             oophorectomy, bilateral salpingectomy); b) physical barrier method (e.g., condom,&#xD;
             diaphragm/sponge/cervical cap) with spermicide; c) non-hormone releasing intrauterine&#xD;
             devices (IUD) or hormone-releasing IUDs (e.g., Mirena or Kyleena); d) vasectomized&#xD;
             partner; and e) post-menopausal and not on hormone replacement therapy.&#xD;
&#xD;
         13. Agrees to an in-clinic confinement of 8 days (7 nights).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal,&#xD;
             hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological&#xD;
             disease, or any other concurrent disease or medical condition that, in the opinion of&#xD;
             the PI, makes the study subject unsuitable to participate in this clinical study.&#xD;
&#xD;
          2. History, presence of, or clinical laboratory test results indicating diabetes.&#xD;
&#xD;
          3. Scheduled treatment for asthma currently or within the past consecutive 12 months&#xD;
             prior to the Screening Visit. As-needed treatment, such as inhalers, may be included&#xD;
             at the PI's discretion pending approval from the Medical Monitor.&#xD;
&#xD;
          4. History or presence of bleeding or clotting disorders.&#xD;
&#xD;
          5. Any history of cancer, except for primary cancers of skin such as localized basal&#xD;
             cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.&#xD;
&#xD;
          6. Systolic blood pressure of &gt; 160 mmHg or a diastolic blood pressure of &gt; 95 mmHg,&#xD;
             measured after being seated for five minutes at Screening and at check-in Day 1.&#xD;
&#xD;
          7. Weight of ≤ 110 pounds.&#xD;
&#xD;
          8. Hemoglobin level is &lt; 12.5 g/dL for females or &lt;13.0 g/dL for males at Screening.&#xD;
&#xD;
          9. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to&#xD;
             become pregnant during the course of the study.&#xD;
&#xD;
         10. A positive urine drug screen without evidence of prescribed corresponding concomitant&#xD;
             medication(s) at Screening or check-in Day 1.&#xD;
&#xD;
         11. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C virus (HCV).&#xD;
&#xD;
         12. Use of any medication or substance that aids in smoking cessation, including but not&#xD;
             limited to any nicotine replacement therapy (e.g., nicotine gum, lozenge, patch),&#xD;
             varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within (≤)&#xD;
             30 days prior to the signing of informed consent.&#xD;
&#xD;
         13. Postpones a decision to quit using tobacco- or nicotine-containing products in order&#xD;
             to participate in this study or self-reports a previous quit attempt within (≤) 30&#xD;
             days prior to the signing the informed consent.&#xD;
&#xD;
         14. Any use of daily aspirin (≥ 325 mg/day) or any use of other anticoagulants.&#xD;
&#xD;
         15. Individuals ≥ 35 years of age currently using systemic, estrogen-containing&#xD;
             contraception or hormone replacement therapy.&#xD;
&#xD;
         16. Whole blood donation within 8 weeks (≤ 56 days) prior to the signing of informed&#xD;
             consent and between Screening and check-in Day 1.&#xD;
&#xD;
         17. Plasma donation within (≤) 7 days prior to signing the informed consent and between&#xD;
             Screening and check-in Day 1.&#xD;
&#xD;
         18. Employed by a tobacco or nicotine company, the study site, or handles tobacco- or&#xD;
             nicotine-containing products as part of their job.&#xD;
&#xD;
         19. Participation in another clinical trial within (≤) 30 days prior to signing the&#xD;
             informed consent. The 30-day window for each subject will be derived from the date of&#xD;
             the last study event in the previous study to the time of signing the informed consent&#xD;
             in the current study.&#xD;
&#xD;
         20. Drinks more than 21 servings of alcoholic beverages per week&#xD;
&#xD;
         21. Has a positive alcohol result at Screening or check-in Day 1.&#xD;
&#xD;
         22. Determined by the PI to be inappropriate for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milly Kanobe, PhD</last_name>
    <role>Study Director</role>
    <affiliation>RAIS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kisha Davis</last_name>
    <phone>336-741-3478</phone>
    <email>davisk8@rjrt.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AMR Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

